Bring more to life.

Are you ready to accelerate your potential and make a real difference within life sciences, diagnostics and biotechnology?

At Radiometer, one of Danaher’s 15+ operating companies, our work saves lives—and we’re all united by a shared commitment to innovate for tangible impact.

You’ll thrive in a culture of belonging where you and your unique viewpoint matter. And by harnessing Danaher’s system of continuous improvement, you help turn ideas into impact – innovating at the speed of life.

At Radiometer, life comes first. Our vision is to improve global healthcare with reliable, fast, and easy patient diagnoses. We’re a team that celebrates diverse ideas and continuous improvement. Here, you’ll find a place to grow and make a real impact, with your unique perspective driving us forward in improving patient care. At Radiometer, our vision is to improve global healthcare with reliable, fast, and easy patient diagnoses.

As a Junior Finance Administrator at Radiometer, you will support day-to-day accounting activities by maintaining accurate financial records, processing accounting transactions, and assisting with account reconciliations. You will help ensure that financial data is recorded in accordance with company policies and support audits, reporting, and month-end closing activities.

This position reports to the Addition to Disposal Finance Manager and is part of the Accounting Team located in Stargard and will be an on-site role.

In this role, you will have the opportunity to:

Accounting and monitoring of fixed assets to ensure full compliance with documentation and reconciling inventories and calculating inventory reserves;
Posting and monitoring of accruals and prepayments to ensure full compliance with documentation;
Providing explanations for deviations/confirming balances/preparing data for audits.

The essential requirements of the job include:

Education in Economics, Finance or Accounting;
1+ years practical work experience in Finance
Fluent Polish and intermediate English
Good knowledge of MS Office in particular of Excel.

It would be a plus if you also possess previous experience in:

Finance;
Experience in data analysis.

Radiometer, a Danaher operating company, offers a broad array of comprehensive, competitive benefit programs that add value to our lives. Whether it’s a health care program or paid time off, our programs contribute to life beyond the job. Check out our benefits at Danaher Benefits Info.

Join our winning team today. Together, we’ll accelerate the real-life impact of tomorrow’s science and technology. We partner with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life.

For more information, visit www.danaher.com.

About the company

Danaher makes instruments, tests and laboratory supplies for drug developers, researchers and clinicians, spanning the path from biological research to clinical patient diagnosis. Its businesses include Cytiva for drug manufacturing, SCIEX for chemical analysis and Beckman Coulter for laboratory testing, linking specialized tools across healthcare workflows. Customers use its equipment to study cells, produce biological medicines and analyze patient samples; the group earns money by selling instruments, reagents, software and support services through its operating companies. Danaher was established in 1984 and is headquartered in Washington, DC.

Company Size

10,001+

Company Stage

IPO

Headquarters

Washington DC, District of Columbia

Founded

1984

Get referred to Danaher

See people who can refer or advise you

Simplify's Take

What believers are saying

Danaher expands bedside testing: its June 2026 Masimo acquisition adds oxygen sensors and patient monitoring.
Careers span Danaher businesses: one HR manager moved through IDBS, Molecular Devices and SCIEX.
Danaher sales are recovering: July 2026 reporting showed second-quarter revenue rising 5.5% from a year earlier.

What critics are saying

Work revolves around targets: Danaher's Business System requires measurable goals and routine progress monitoring.
Danaher's respiratory test demand fluctuates: illness severity determines sales volumes outside management's control.
Spin-offs leave Danaher exposed: Veralto and Fortive separations retain tax indemnity risks.

What makes Danaher unique

Danaher standardizes improvement: its Business System applies shared methods across every operating company.
Danaher preserves business identities: its decentralized structure keeps acquired companies distinct within the group.
Repeat purchases anchor Danaher Diagnostics: 89% of segment sales come from consumables, services and equipment leases.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Limited
Paid Vacation
Paid Holidays
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Hybrid Work Options
Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

-1%

2 year growth

-11%

Insider Monkey

Oct 18th, 2026

Roper Technologies (ROP) vs. Danaher (DHR): which is the better long-term capital allocator?

Roper Technologies (ROP) vs. Danaher (DHR): which is the better long-term capital allocator? Roper Technologies and Danaher share a proven acquisition-driven strategy, but Roper's combination of cash generation, disciplined dealmaking, and valuation makes it the more compelling long-term investment today. Published October 18, 2026 at 10:48 am EDT Roper Technologies, Inc. (NASDAQ:ROP) and Danaher Corporation (NYSE:DHR) have returned 4.01% and 18.97%, respectively, over the last six months, as of October 15. This compares to a 21.5% return for the Insider Monkey Billionaire Index and 15.74% for the State Street SPDR S&P 500 ETF Trust. Both have built their businesses around a similar idea: acquire companies with attractive economics, improve their operations, and use the resulting cash flows to fund future growth. Both have proven that this approach can create substantial shareholder value. However, Roper currently has a more compelling combination of cash generation, acquisition discipline, and valuation. Both businesses are generating cash, but their growth profiles and end markets differ considerably. Roper Technologies, Inc. ranks 10th in our list of 10 Best Stocks to Buy for the Next 20 Years. Click HERE to find out other stocks on the list. Capital allocation is the real differentiator. Roper's strategy revolves around acquiring specialized businesses, particularly vertical-market software companies with recurring revenue, high customer retention, and products embedded in essential workflows. These businesses can be difficult to replace because customers depend on them to run critical operations. That creates a relatively predictable cash flow base, which Roper can use to finance further acquisitions. The company reported enterprise software gross retention in the mid-90% range during the second quarter. Organic recurring revenue across its software segments grew 7%, faster than its overall organic growth rate. Management is also developing AI capabilities across its portfolio, potentially allowing its businesses to automate more customer workflows and expand their addressable markets. Danaher takes a slightly different approach. Its Danaher Business System is built around making its businesses run better, whether that means improving efficiency, cutting costs, or getting products to market faster. The company applies this playbook across its biotechnology, life sciences, and diagnostics businesses, all of which stand to benefit from growing demand for biologic drugs, better diagnostic tools, and advances in healthcare. Danaher's acquisition of Masimo, which closed in June, illustrates this strategy. Management expects the deal to be immediately accretive to adjusted earnings and sees opportunities to improve productivity, strengthen innovation, and capture customer synergies. Danaher also announced the acquisition of StatLab, a pathology consumables manufacturer with more than 85% recurring revenue. The distinction is that Roper's portfolio is heavily oriented toward specialized software and technology, while Danaher has greater exposure to scientific equipment, consumables, and healthcare-related demand. Danaher's business model can benefit from a recovery in biotech investment, but its latest results also show how customer shipment delays and uneven research spending can affect growth. Its bioprocessing business remains a promising long-term opportunity, although several large shipments were postponed during the second quarter. Neither approach is necessarily better. Roper benefits from recurring software revenue and the fact that customers are reluctant to switch systems they rely on every day. Danaher, meanwhile, has a strong track record of improving the businesses it acquires. But both strategies depend on one thing: finding the right businesses at the right price. Even a great company can become a poor investment if management pays too much for growth. Valuation gives Roper the edge. The biggest difference between these two stocks right now is what investors are paying for them. Roper trades at 15.16x trailing earnings and 14.97x forward earnings, compared with 39.41x and 23.81x, respectively, for Danaher. That's a sizable gap, especially considering that Roper's organic revenue grew 5% in the second quarter, while Danaher's core revenue increased 3%. Danaher has good reasons to command a premium. Its businesses are tied to healthcare innovation, and a recovery in life sciences spending could give earnings a lift. Recent results also suggest that demand is improving across several parts of the business. The question is how much of that recovery is already reflected in the stock. Danaher expects core revenue to grow 3% to 4% in 2026, with growth picking up toward a mid-single-digit rate by the fourth quarter. That's encouraging, but the recovery is still playing out. If it takes longer than expected, investors paying a premium valuation could be left disappointed. Roper has its own challenges. Its acquisition strategy only works if it can keep finding good businesses at sensible prices. Net debt stood at 3.4x EBITDA at the end of the second quarter, so management has some balance-sheet work to do before pursuing its next major deals. The company expects strong cash generation and proceeds from its Indicor investment to help bring leverage down. It also needs to show that its investments in AI can translate into real growth, rather than simply keeping its products competitive. Roper looks more reasonably priced here. It has a solid base of recurring revenue and generates plenty of cash, yet its stock trades at a much lower multiple than Danaher's. The two companies have different business models, so the comparison isn't perfect, but Danaher's premium is hard to justify unless its expected recovery translates into stronger growth and earnings. Conclusion. Roper Technologies comes out ahead at these valuations. Danaher is a well-run business with plenty of room to benefit from a recovery in life sciences, but investors are paying considerably more for that opportunity. Roper's combination of recurring revenue, disciplined capital allocation, and strong cash flow offers a more appealing starting point for long-term investors, provided management continues to make sensible acquisitions and brings leverage down. Roper's advantage is not simply that it buys businesses. It is that it owns specialized companies with durable customer relationships and uses their cash flows to support further compounding. If management maintains its acquisition discipline and reduces leverage, Roper appears better positioned to deliver attractive long-term returns without requiring as much optimism to be priced into the stock. Market sentiment. Roper Technologies saw hedge fund ownership decline in Q2 2026, with 41 funds holding the stock, down from 49 in the previous quarter. However, the combined value of their holdings remained almost unchanged at around $4.95 billion, suggesting that the decline in the number of holders did not translate into a meaningful reduction in the total capital invested. Danaher saw a similar dip in the number of hedge funds holding its shares, falling from 110 in Q1 to 108 in Q2 2026. However, the combined value of those holdings increased from approximately $10.12 billion to $10.92 billion. So while slightly fewer funds held Danaher, the total value of their positions grew over the quarter.

PR Newswire

Oct 12th, 2026

Danaher adds ex-CFO Daniel Comas and Robert Hershberg to board, expanding it to 13 directors

Danaher Corporation has appointed Daniel Comas and Robert Hershberg to its board, which grows from 11 to 13 directors. The appointments took effect on October 9, 2026. Comas joined Danaher in 1991 and was chief financial officer from April 2005 through December 2018. He also sits on the boards of Fortive Corporation and Veralto Corporation. Hershberg, a medical doctor, was chief executive officer of HilleVax from March 2020 through September 2025. He previously served as chief scientific officer at Celgene Corporation and joins Danaher's Science and Technology Committee. Director Alan Spoon will retire from the board at the 2027 annual shareholder meeting. Separately, co-founders Steven and Mitchell Rales each waived 500,000 restricted stock units from their August 4, 2026 awards.

Yahoo Finance

Oct 7th, 2026

Danaher to launch AI-powered autonomous lab to accelerate drug discovery eightfold by 2027

Danaher Corporation announced plans to launch its first AI-powered autonomous research lab at Abcam, expected to reach full capacity in early 2027. The facility will use artificial intelligence and robotics to develop custom antibodies and molecular tools through a continuous design-make-test-learn cycle. The lab integrates capabilities from multiple Danaher companies, including Beckman Coulter Life Sciences, Cytiva, and Molecular Devices. Robotic automation was developed with Automata, in which Danaher invested in January 2026. Danaher projects the system will deliver up to eight times faster progress from concept to validated reagent and increase annual reagent generation tenfold, scaling from tens to hundreds per year. The company described the lab as the first step towards building a fleet of smart instruments producing AI-ready data, which would connect to create integrated workflows and additional autonomous labs.

Healthcare Digital

Sep 28th, 2026

Shashanka Muppaneni named Danaher Chief Strategy Officer.

Shashanka Muppaneni named Danaher Chief Strategy Officer. September 28, 2026 Shashanka Muppaneni has been appointed SVP and Chief Strategy Officer at Danaher, while Brad Gray will step down as SVP of Strategic Development Life sciences and diagnostics company Danaher has announced changes to its strategy leadership team as it prepares for a broader transition at the top of the business. Effective 1 October 2026, Shashanka Muppaneni will become SVP and Chief Strategy Officer, moving from his current role as Group Vice President of Strategy and Business Development for Danaher's Diagnostics platform. The appointment comes as Julie Sawyer Montgomery prepares to take over as Danaher's President and CEO on the same date. Julie, who has led the company's Diagnostics platform, has played a key role in its growth, with the business increasing from approximately US$6bn in revenue in 2017 to around US$11bn in 2025. Julie says Shashanka "pairs sharp strategic thinking with a pragmatic, results-oriented approach," adding that he has demonstrated an ability to align strategy with business execution, deliver strategic M&A and build partnerships across Danaher's businesses. "He will be a strong partner as we accelerate Danaher's strategy and M&A agenda in the years ahead," she says. Danaher generated US$24.6bn in revenue in 2025 and operates across biotechnology, diagnostics and life sciences. Its portfolio includes businesses such as Cytiva, Beckman Coulter, Cepheid, Leica Biosystems and Masimo, spanning drug development, biomanufacturing, diagnostics and patient monitoring. Deep strategic and healthcare experience. Shashanka brings almost two decades of experience across strategy, healthcare and life sciences to his new role. He began his career in finance and strategy-oriented positions at Thomson Reuters and Microsoft before moving into healthcare-focused roles at Smiths Group and Upsher-Smith Laboratories. Danaher: Key Facts * US$24.6bn - Danaher's full-year revenue in 2025. * US$10bn - Annual revenue of Danaher's Diagnostics business in 2025. * US$9.9bn - Value of Danaher's 2026 acquisition of Masimo. * 1 October 2026 - Shashanka Muppaneni becomes Chief Strategy Officer. * 2024 - Year Shashanka joined Danaher's Diagnostics business. He subsequently held two positions at Boston Consulting Group, including Managing Director and Partner, as well as roles with life sciences companies including Illumina and Seer. Shashanka joined Danaher in 2024 to lead Strategy and Business Development for the Diagnostics platform, where his remit included strategic planning and M&A. His tenure has included Danaher's acquisition of Masimo, a specialty diagnostics and patient monitoring company. Danaher completed the US$10bn transaction in June 2026, adding Masimo as a standalone operating company within its Diagnostics segment. His experience in healthcare strategy and transactions is likely to be particularly relevant as Danaher continues to reshape its portfolio and identify opportunities for growth. Brad Gray to step down. Shashanka's appointment coincides with the departure of Brad Gray, Danaher's current SVP of Strategic Development. Brad has played a leading role in streamlining Danaher's strategy and M&A approach and supporting the deployment of more than US$10bn in capital since he joined in 2024. On LinkedIn, following the announcement of his departure, Brad writes: "These past two years shaping Danaher's strategy and M&A agenda have been amazing. I am proud of what our BD and Strategy teams accomplished together, from acquiring Masimo to laying out Danaher's enterprise strategy for the future. Thank you to this amazing team for the trust, partnership and hard work." He will remain with the company in an advisory capacity until March 2027. "I am proud of what our BD and Strategy teams accomplished together, from acquiring Masimo to laying out Danaher's enterprise strategy for the future. " Brad GrayOutgoing SVP of Strategic Development at Danaher Danaher prepares for leadership transition. The changes to Danaher's strategy leadership come as the company prepares for a broader executive transition. Julie will become President and CEO on 1 October 2026, succeeding Rainer Blair, who has led the company since 2020. Rainer will retire from the role and remain with Danaher as a senior adviser until 31 March 2027 to support the transition. Danaher has also announced that Heathre Moler will become Chief Human Resources Officer from 1 October 2026. The leadership changes come as Danaher enters its next phase of growth following a strong 2025. The company reported full-year revenue of US$24.6bn, up 3% year-on-year, while its acquisition strategy remains an important component of portfolio development. With Shashanka taking responsibility for corporate strategy and M&A, Danaher's leadership team will be tasked with building on that momentum while continuing to identify opportunities across its biotechnology, life sciences and diagnostics businesses. Key Danaher partners. CEO: Joe Kiani | HQ: Irvine, California Masimo develops non-invasive patient monitoring technologies, including pulse oximetry, sensors and connectivity platforms. Danaher completed its US$9.9bn acquisition in June 2026, making Masimo a wholly owned subsidiary within its Diagnostics segment while retaining the Masimo brand and standalone operating structure. AstraZeneca CEO: Pascal Soriot | HQ: Cambridge, UK AstraZeneca is a global biopharmaceutical company focused on oncology, rare diseases and biopharmaceuticals. In 2025, it partnered with Danaher to develop and commercialise novel diagnostics for precision medicine, initially focusing on digital and computational pathology and AI-assisted algorithms through Danaher's Leica Biosystems. The collaboration aims to improve identification of patients most likely to benefit from targeted therapies. Innovaccer CEO: Abhinav Shashank | HQ: San Francisco, California Innovaccer is a healthcare AI and data company providing platforms designed to connect healthcare data and support clinical decision-making. Danaher announced an investment partnership with Innovaccer in January 2025, combining Danaher's diagnostics expertise with Innovaccer's data and AI capabilities to advance diagnostic and clinical AI solutions. Executives. * Brad Gray SVP, Strategic Development * Julie Sawyer Montgomery President * Shashanka Muppaneni Chief Strategy Officer Company Portals

GlobeNewswire

Sep 23rd, 2026

MaxCyte appoints Sidharth Kapileshwar as Chief Corporate Development Officer.

MaxCyte appoints Sidharth Kapileshwar as Chief Corporate Development Officer. September 23, 2026 08:05 ET | Source: MaxCyte, Inc ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) - MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. "Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the world. He knows firsthand what it takes to translate strategy into growth," said Maher Masoud, President and Chief Executive Officer. "I am confident that Sidharth's expertise will support MaxCyte's next chapter of growth." Mr. Kapileshwar joins MaxCyte from Danaher Corporation, where he most recently served as Vice President of Innovation for the company's Life Sciences Platform, leading enterprise-wide innovation programs. Over nearly 25 years, he has held corporate development, strategy, innovation, and M&A leadership roles at global life sciences and technology companies, including GE Healthcare, Beckman Coulter, and Halma plc. Mr. Kapileshwar holds a Master of Science in Engineering from The Ohio State University, an MBA from the University of Chicago Booth School of Business, and a Bachelor of Technology in Engineering from the Indian Institute of Technology Bombay. "MaxCyte has been an early pioneer in applying flow electroporation at clinical and commercial scale for cell and gene therapies, and its technologies are foundational to where the field is headed. That's exactly the kind of opportunity I want to help build at MaxCyte," said Sidharth Kapileshwar. "I've spent my career helping large, global organizations sharpen their strategies and execute their next phase of growth, and I'm excited to bring that same momentum to MaxCyte." About MaxCyte At MaxCyte(R), we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation(R) technology and SeQure DX(TM) gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn. MaxCyte Contacts: Investor Relations Gilmartin Group Erik Abdow [email protected] Media Contact Oak Street Communications Kristen White +1 415-608-6060 [email protected]

Danaher

Junior Finance Administrator

About the job